Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of tunicamycin in preparing tumour cell reversing drug

A technology of tumor cells and tunicamycin, applied in the field of medicine, can solve the problems of weak basic research field and blank clinical research, and achieve the effect of small influence, exact effect and low drug dosage

Inactive Publication Date: 2009-09-16
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Compared with the remarkable achievements in acute promyelocytic leukemia, the field of basic research in the induction of differentiation therapy for multiple myeloma and other tumors is very weak, and clinical research is still blank

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tunicamycin in preparing tumour cell reversing drug
  • Application of tunicamycin in preparing tumour cell reversing drug
  • Application of tunicamycin in preparing tumour cell reversing drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1: U266 myeloma cells treated with tunicamycin

[0019] Types and sources of reagents: tunicamycin was purchased from Sigma Company in the United States, loan number T7765, made into 5 mg / mL mother solution with DMSO, stored at 4°C for later use, and diluted with RPMI-1640 culture solution containing 10% fetal bovine serum to the required concentration The required concentration (0.25 μg / ml or 0.5 μg / ml), wherein the content of DMSO is lower than 0.1%, the effect of DMSO on cells can be neglected under this concentration condition (see literature Hou J, Xiong H, Gao W, Jiang H.2-Methoxyestradiol at low dose induces differentiation of myeloma cells. Leuk Res. 2005; 29: 1059-1067, under this low concentration condition, the effect of DMSO on cells is negligible). The Elisa Kit for detecting the λ chain content in the supernatant was produced by Bethy Company in the United States, the loan number is E80-116, and it was operated according to the instructions. CD49e...

Embodiment 2

[0023] Example 2: RPMI-8226 myeloma cells treated with tunicamycin

[0024] The kind and source of reagent: with embodiment 1.

[0025] Cells and culture method: the myeloma cell line RPMI-8226 was purchased from the Chinese Academy of Sciences, and the rest were the same as in Example 1.

[0026] The method of the experiment: the cells in the proliferating phase were taken for the experiment, and the inoculated cell density was 1×10 5 / L, the concentration of tunicamycin was set to 0, 0.25 μg / ml, and 0.5 μg / ml. After culturing for 48 hours and 72 hours respectively, the supernatant was collected by centrifugation, and the content of the supernatant chain was measured with an Elisa kit. After Wright's staining, the morphological changes were observed; a part of the cells were labeled with CD49e and flow cytometry was used to detect the expression of CD49e.

[0027] Results: Compared with the control cells, after the myeloma cell lines were treated with low dose of tunicamyci...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Concentrationaaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of medication. The tumour is always cured by operation, irradiation and chemical medication, and the induction differentiation therapy of malignant tumour becomes the research hotpot and frontier field of cancer biology and tumor therapeutics at present. The invention aims at providing a now application of tunicamycin which is the application in preparing a tumour cell reversing drug. The concentration of low-dosage tunicamycin adopted by the invention is 0.1-0.5mug / ml. After a myeloma cell line is treated, myeloma cell strain is differentiated in state, which is shown as cells are transited into mature plasma cell state; cell differentiation antigen CD49e is raised; and excreted immune globulin light chains are also increased. The invention has the advantages of low drug dosage of the tunicamycin, exact effect, less influence on normal cell and benefit for improving the living state of tumour patients.

Description

technical field [0001] The invention relates to the technical field of medicine, and relates to a technique for using tunicamycin in the preparation of tumor cell reversal drugs. Background technique [0002] As we all know, for more than 100 years, the treatment of tumors has been using surgery, radiation and chemical drug therapy, especially for hematological tumors including myeloma, combined chemotherapy, which does not distinguish between friend and foe, focuses on killing tumor cells. In 1986, Chinese scientists were the first in the world to use all-trans retinoic acid to induce differentiation in the treatment of acute promyelocytic leukemia and achieved remarkable results, creating a new era in the induction of differentiation in the treatment of tumors. The proposal of inducing differentiation therapy breaks the view that "once it becomes a cancer cell, it will always be a cancer cell". At present, the induction and differentiation therapy of malignant tumors has ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7072A61P35/00
Inventor 邹剑峰侯健姜华
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com